Compare Cenovus Energy Inc (CVE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Viatris Inc — how do they compare? Cenovus Energy Inc trades at $31.36 (market cap $57.90B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Cenovus Energy Inc is far larger — about 2.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Viatris Inc for 57 Days on average.
| CVE | VTRS | |
|---|---|---|
Market Cap | $57.90B | $20.03B |
Volume | 7,863,588 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $33.92 | $18.27 |
52-Week Low | $15.85 | $9.74 |
Typical Hold Time | 46 Days | 57 Days |
Enterprise Value | $63.84B | $32.15B |
Dividend Yield | 1.97% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.39, up 2.48% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with a P/E of 12.43, ROE of 20.96%, and consistent earnings beats in recent quarters. Recent analyst upgrades and positive media coverage highlight growing optimism around the company's growth prospects and attractive valuation metrics.
CVE presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors should monitor energy price volatility and execution risks. The company's improving cash flow outlook and shareholder returns through dividends provide additional support for long-term value creation.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
